|
| |
|
 |
BioPortfolio
Bulletin
|
| www.bioportfolio.com |
http://www.bioportfolio.co.uk/bulletin_56.htm
October
5th 2004
|
|
|
|
|
BIO/PHARMA
EXCHANGE #10 AUCTION. A Major Sale of Biotechnology, Pharmaceutical and
Medical Equipment Featuring Assets From Pfizer Japan and Other Bio/Pharm
Companies. Online Bidding Begins October 20, 9am (PT) at DoveBid's
Website: www.dovebid.com.
Assets Located in USA, Japan and Europe. For More Information,
Visit Our Website or Call 800-665-1042.
http://www.dovebid.com/Auctions/AuctionDetail.asp?auctionID=2624&referraltag=biop10a
|
In this Week's issue:
- Osteoarthritis treatment and
markets post VIOXX - reports, news, opinions
- NEWS - BioNews
Headlines and content - over
400 life science
industry news stories per day [more]
- CAREERS - 100's of
jobs - 3:1 deal for recruiters [more]
|
| Osteoarthritis
treatment and markets post VIOXX - reports, news, opinions |
| Special
Report
NEW
REPORT: COX-2
withdrawal - Therapeutic, R&D and pharmaceutical impact
NEWS
ITEMS:
BIOWEB
searches:
COX-2
withdrawal - Therapeutic, R&D and pharmaceutical impact
As hurricane season continues in the US, forces of a very different
nature have blown through the pharmaceutical industry with Merck's
withdrawal of the blockbuster Vioxx (Rofecoxib) from the market. This
move was in response to new, three-year data from a prospective,
randomized, placebo-controlled clinical trial, the APPROVe (Adenomatous
Polyp Prevention on VIOXX) trial. The trial, which is being stopped, was
designed to evaluate the efficacy of VIOXX in preventing recurrence of
colorectal polyps in patients with a history of colorectal adenomas. In
this study, there was an increased relative risk for confirmed
cardiovascular events, such as heart attack and stroke, beginning after
18 months of treatment in the patients taking VIOXX compared to those
taking placebo. So what will be the impact of this key pharmaceutical
event? Pfizer have affirmed the safety of their COX-2 inhibitor Celebrex
(celecoxib); the FDA has stated that they will now be looking at other
COX-2 inhibitors more carefully impacting on newer agents such as
Merck's Arcoxia, and Novartis' Prexige; and others are suggesting that
now is the time to push forward other therapeutic classes that can
reduce the pain of osteoarthritis such as the NO-NSAIDs and LOX/COX
inhibitors as well as osteoarthritis disease modifying agents. As the
dust settles LeadDiscovery is publishing a special report on the impact
of Vioxx's withdrawal.
TABLE OF CONTENTS
- The biology of the cyclooxygenase
pathway
- The rational for COX-2 development
- Clinical data on approved and late
stage COX-2 inhibitors
- Sales figures for COX-2 inhibitors
- Adverse effects of COX-2 inhibitors
- Differentiating the risk of COX-2
inhibitor family members
- Knock-on effect of Vioxx's withdrawal
- Estimated sales performance of other COX-2 inhibitors
- Emerging alternatives to COX-2
inhibitors (NO-NSAIDs, LOX/COX inhibitors, DMOADs)
October 2004. PDF format
Price:
$795.00 / £429.30
To order click belew:
http://www.bioportfolio.com/cgi-bin/acatalog/Bioportfolio_LeadDiscovery_14.html
OTHER REPORTS:
|
| NEWS
- BioNews Headlines and content |
| Every
30 minutes BioPortfolio updates the BioNews service with the latest news
items collated from thousands of published sources. In addition we
carry full text press releases for over 300 which are added to the site
daily at 12:30 GMT.
To full evaluate the
service and to take advantage of our email alert service visit:
BioWatch BioNews Tracking:
http://www.bioportfolio.com/news_tracking/index.htm
To search go to:
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?FILE=search&SAVEDB=news
|
| CAREERS
- Job Seekers and Employers |
|
Job Seekers
Careers
Home Page
|
|
Employers
The BioJobNetwork can help you get your Fall recruiting on the fast
track. Reach candidates through our network of thirteen career centers
catering to the biosciences professional. Submit your listings to
display on all thirteen career centers and broaden your visibility and
reach.
Login
your BioPortfolio employer account now.
About the BioJobNetwork Posting
Package:
- Use Coupon RP77UK5
to post 3 jobs for $125. Enter coupon at login.
- Each posting runs for 60
days.
- Coupon is good through
October 30th.
- Reach 13 industry sites
with a single posting: BiotechCareerCenter, BioJobNet, BioPortfolio,
BioProcessing International, Drug Delivery Technology, EyeforPharma,
International Association of Nanotechnology, MolBiol, NanoBiotech
News, Society For Biomaterials, Society for Bioprocessing
Professionals, and ThePharmaNetwork. More partners soon to be
announced!
http://www.biojobnetwork.net/bioportfolio/?a=employer
|
| |
Contact
us:
Editorial and features: peter.barfoot@bioportfolio.com
Subscriber
information:
To subscribe for the
BioPortfolio Bulletin in HTML, email:
bioportfolio-subscribe-request@peach.ease.lsoft.com
To
unsubscribe, email: bioportfolio-signoff-request@peach.ease.lsoft.com
WITH NO SUBJECT. The system will automatically remove your email
address from the list based on your email address. If your
email has changed please email peter.barfoot@bioportfolio.com
with a list of your email address and we will manually unsubscribe for
you. Thank you for your understanding.
©2004
BioPortfolio Limited - http://www.bioportfolio.com
and http://www.bioportfolio.co.uk
|
|
| |
|
